Advanced search
Publication Cover
Journal of Obstetrics and Gynaecology Volume 40, 2020 - Issue 2
Submit an article Journal homepage
171
Views
2
CrossRef citations to date
0
Altmetric
Original Articles

Does a history of malignancy impact the survival of a subsequent endometrial adenocarcinoma? Should clinical trials eligibility criteria be revisited?

Hadeer H. MohamedOncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-3483-9827
ORCID Icon,
Mai Ibrahim SokkarObstetrics and Gynecology Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt
,
Ahmed M. AfifiOncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt;
,
Anas M. SaadOncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-0101-0131
ORCID Icon,
Sali AlbaroukiOncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt;
&
Muneer J. Al-HusseiniOncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt;
Pages 233-239 | Published online: 29 Jul 2019

References

  • Brown J, Smith JA, Ramondetta LM, Sood AK, Ramirez PT, Coleman RL, et al. 2010. Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial. Cancer 116:4973–4979.
  • Chlebowski RT, Schottinger JE, Shi J, Chung J, Haque R. 2015. Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors. Cancer 121:2147–2155.
  • Chow CJ, Habermann EB, Abraham A, Zhu Y, Vickers SM. 2013. Does enrollment in cancer trials improve survival? Journal of the American College of Surgeons 216:774–781.
  • Coyte A, Morrison DS, McLoone P. 2014. Second primary cancer risk—the impact of applying different definitions of multiple primaries: results from a retrospective population-based cancer registry study. BMC Cancer 14:272.
  • Cronin KA, Lake AJ, Scott S, Sherman RL, Noone AM, Howlader N, et al. 2018. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. Cancer 124:2785–2800.
  • de Moor JS, Mariotto AB, Parry C, Alfano CM, Padgett L, Kent EE, et al. 2013. Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiology Biomarkers and Prevention 22:561–570.
  • Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, et al. 2014. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 120:1290–1314.
  • Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. 2015. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer 136:E359–E386.
  • Gerber DE, Laccetti AL, Xuan L, Halm EA, Pruitt SL. 2014. Impact of prior cancer on eligibility for lung cancer clinical trials. Journal of the National Cancer Institute 106:pii: dju302.
  • Homesley HD, Filiaci V, Gibbons SK, Long HJ, Cella D, Spirtos NM, et al. 2009. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecologic Oncology 112:543–552.
  • Laccetti AL, Pruitt SL, Xuan L, Halm EA, Gerber DE. 2015. Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual. Journal of the National Cancer Institute 107:pii: djv002.
  • Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. 2016. Cancer treatment and survivorship statistics, 2016. CA: A Cancer Journal for Clinicians 66:271–289.
  • Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). 2019. SEER Cancer Statistics Review, 1975-2016. Bethesda, MD: National Cancer Institute. https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission, posted to the SEER web site, April 2019.
  • Ongoing Study 1. 2016. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02990728?cond=Endometrial+Cancer&rank=1
  • Ongoing Study 2. 2016. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02912572?cond=Endometrial+Cancer&rank=7
  • Pruitt SL, Laccetti AL, Xuan L, Halm EA, Gerber DE. 2017. Revisiting a longstanding clinical trial exclusion criterion: impact of prior cancer in early-stage lung cancer. British Journal of Cancer 116:717–725.
  • Ryerson AB, Eheman CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, et al. 2016. Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer 122:1312–1337.
  • Saad AM, Al-Husseini MJ, Elgebaly A, Aboshady OA, Salahia S, Abdel-Rahman O. 2018. Impact of prior malignancy on outcomes of stage IV esophageal carcinoma: SEER based study. Expert Review of Gastroenterology and Hepatology 12:417–423.
  • Siegel RL, Miller KD, Jemal A. 2018. Cancer statistics, 2018. CA: A Cancer Journal for Clinicians 68:7–30.
  • Smyth EC, Tarazona N, Peckitt C, Armstrong E, Mansukhani S, Cunningham D, Chau I. 2015. Exclusion of gastrointestinal cancer patients with prior cancer from clinical trials: is this justified? Clinical Colorectal Cancer 15:e53–e59.
  • Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. 2015. Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians 65:87–108.
  • Tournoux C, Katsahian S, Chevret S, Levy V. 2006. Factors influencing inclusion of patients with malignancies in clinical trials: a review. Cancer 106:258–270.
  • Van Spall HGC, et al. 2007. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA 297:1233–1240.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.